August 26, 2024 06:18 AM EDT
Deals
China
Pharma

Mubadala, CBC Group ink $680M deal for UCB’s neu­rol­o­gy and al­ler­gy port­fo­lio in Chi­na

Amber Tong

Bel­gian phar­ma UCB is sell­ing parts of its Chi­na busi­ness to Mubadala and CBC Group for $680 mil­lion. In ad­di­tion to tak­ing over UCB’s ma­ture …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

Neu­ro­crine culls Phase 2 neu­ropsych med af­ter fail­ing to val­i­date ear­li­er da­ta

Bicara, Zenas and MBX rekin­dle IPO mar­ket with rare Fri­day triple­head­er

Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO

A service from the Financial Times